Trevi Therapeutics, Inc.
TRVINasdaqCIK 1563880HealthcareFiscal year ends Dec 31
Reports and events: 134 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0616:12 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-338023 |
| 2026-08-0616:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337974 |
| 2026-06-0416:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257365 |
| 2026-05-0718:23 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-26-000382 |
| 2026-05-0516:09 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-206390 |
| 2026-05-0516:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206382 |
| 2026-04-2116:00 ET | DEF 14A | Proxy statementPeriod 2026-04-21 | 0001193125-26-166695 |
| 2026-04-1708:06 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-160355 |
| 2026-03-1716:08 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-110783 |
| 2026-03-1716:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-110767 |
| 2026-03-0916:35 ET | 8-K | 8.01 Other events | 0001193125-26-098676 |
| 2026-02-1316:05 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-26-000150 |
| 2025-12-0508:58 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-308769 |
| 2025-11-1316:09 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-280166 |
| 2025-11-1316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-280149 |
| 2025-08-2016:31 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001563880-25-000005 |
| 2025-08-1118:56 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-25-000533 |
| 2025-08-0716:19 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-105066 |
| 2025-08-0716:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-105011 |
| 2025-06-1717:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-087486 |
| 2025-06-0416:18 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-134913 |
| 2025-06-0216:02 ET | 8-K | 8.01 Other events | 0001193125-25-133273 |
| 2025-06-0209:31 ET | 8-K | 8.01 Other events | 0001193125-25-132890 |
| 2025-05-0816:16 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-067011 |
| 2025-05-0816:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066971 |
| 2025-04-2910:14 ET | DEF 14A | Proxy statementPeriod 2025-04-29 | 0000950170-25-059628 |
| 2025-03-2019:55 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001072613-25-000239 |
| 2025-03-1816:14 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-041194 |
| 2025-03-1816:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-041187 |
| 2025-03-1017:03 ET | 8-K | 8.01 Other events | 0000950170-25-036503 |
| 2025-01-0808:00 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-003286 |
| 2024-12-1617:20 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-279715 |
| 2024-12-1208:00 ET | 8-K | 8.01 Other events | 0000950170-24-135602 |
| 2024-12-0317:20 ET | 8-K | 8.01 Other events | 0000950170-24-132883 |
| 2024-11-0818:57 ET | SC 13D/A | Ownership report, active investor, amended | 0001072613-24-000813 |
| 2024-11-0616:20 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122355 |
| 2024-11-0616:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122316 |
| 2024-10-2110:43 ET | 8-K | 8.01 Other events | 0000950170-24-115800 |
| 2024-10-0408:07 ET | 8-K | 8.01 Other events | 0000950170-24-112729 |
| 2024-10-0117:37 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-110462 |
| 2024-08-0816:13 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093983 |
| 2024-08-0816:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093942 |
| 2024-06-1317:01 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-073129 |
| 2024-05-2118:34 ET | SC 13D/A | Ownership report, active investor, amended | 0001072613-24-000518 |
| 2024-05-0716:11 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-054489 |
| 2024-05-0716:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-054478 |
| 2024-04-2616:38 ET | DEF 14A | Proxy statementPeriod 2024-06-13 | 0000950170-24-049234 |
| 2024-03-2016:10 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-034167 |
| 2024-03-2016:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-034159 |
| 2023-11-0916:13 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062063 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:29 ET. Listed shows no prices and gives no investment advice.